Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a phase I multicentre randomized, open, parallel-arm clinical trial conducted to investigate the IMP, namely 111In-CP04.

The study consists of preclinical (to establish a clinically useful formulation for the radiolabelled peptide CP04), and a clinical step. The main objective of the clinical part of the project is to establish the safety of i.v. administration of a high peptide amount and to assess the tracer biodistribution and dosimetry in MTC and normal tissues and to determine critical organs as well as the evaluation of the potential of CCK2 receptor scintigraphy to detect cancer lesions for both low (10ug) and high (50ug) peptide amount and the decrease of kidney dose after co-administration of gelofusine /gelaspan as a nephroprotective agent. To achieve this, the following study design has been accepted: the first 4 patients will receive 2 peptide amount of CP04: low peptide amount (for diagnostic purpose) and high peptide amount (for therapeutic purpose) of CP04. If no SAE is present, the remaining pts will be randomized for 2 arms: high peptide amount of 111In-CP04 with and without gelofusine/gelaspan infusion.

It is expected that CCK-2/gastrin receptor imaging will become a valid diagnostic method for a specific non-invasive staging and follow-up of patients with MTC, and treatment of recurrent and disseminated disease will be more efficient with minimized nephro- and myelotoxicity (if 111In labelled).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

NCT04619316

Metastatic Thyroid Cancer

UNKNOWN PHASE2

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

NCT00094055

Thyroid Neoplasms

COMPLETED PHASE2

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

NCT00095836

Head and Neck Cancer

COMPLETED PHASE2

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

NCT00389441

Thyroid Neoplasms

COMPLETED PHASE2

Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine

NCT02773667

Thyroid Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main goal of the study is to expand cancer preclinical research results on the usefulness of CCK-2/gastrin receptor in clinical practice. On the basis of last few years preclinical research outcome on new biomarkers, conjugate CP04 was chosen on the basis of its good stability and affinity to CCK-2/gastrin receptor in vitro, as well as its favourable biodistribution and pharmacodynamic properties in vivo, preclinically. Within this project the tracer may get a chance to be introduced to clinical practice as a more selective and efficient tool for the diagnosis, early detection and therapy of recurrent and metastatic MTC.

Furthermore, the project may become the first step to establish a new, more effective strategy for the treatment of MTC patients leading to reduction of incidence and mortality as well as improvement of quality of life. CCK-2/gastrin receptors may become viable targets for radionuclide scintigraphy and radionuclide therapy, similarly to somatostatin receptors which have been instrumental to establish nuclear medicine efficacy in clinical practice. Achieving key project objectives (i.e. investigation of patients after administration of high peptide amount of the CCK-2/gastrin receptor labelled compound, performing complete patient peptide assessment and research nephrotoxicity in patients with or without administration for nephroprotective agent gelofusine/gelaspan), we will be able to define the exact molecular profile of an individual patient and tumour. Eventually, safe and efficacious personalized treatment will be planned using radiolabelled CCK-2/gastrin ligands of higher therapeutic efficacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medullary Thyroid Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

arm 1

111In-CP04

Group Type EXPERIMENTAL

111In-CP04

Intervention Type DRUG

Radiopharmaceutical preparation

arm 2

111In-CP04 with co-administration of gelofusine/gelaspan

Group Type EXPERIMENTAL

111In-CP04 with co-administration of gelofusine/gelaspan

Intervention Type DRUG

Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

111In-CP04

Radiopharmaceutical preparation

Intervention Type DRUG

111In-CP04 with co-administration of gelofusine/gelaspan

Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Related to the medullary cancer of the thyroid:

1. Histologically documented medullary cancer of the thyroid.
2. Presence of more than one distant or nodal, surgically untreatable metastases confirmed with either 18F-FDG PET/CT or enhanced-CT or MRI OR
3. Doubling time (DT) of serum calcitonin level less than two years prior to study entry and negative imaging.
4. Karnofsky performance status \> 50%.
5. Life expectancy of more than 6 months.

Related to the patient:
6. Male or female patients aged \>18 years without upper age limit.
7. Ability to understand and willingness to sign a written informed consent document.
8. Written informed consent obtained according to international guidelines and local laws.

Exclusion Criteria

Related to the MTC:

1. Patients with surgically treatable medullary thyroid cancer.
2. Patients with history of second malignancy other than basal cell carcinoma of the skin.

Related to previous or concomitant therapies :
3. Participation in any other investigational trial within 3 months of study entry.
4. Previous external beam radiation therapy within two years.
5. Organ allograft requiring immunosuppressive therapy.

Related to the patient:
6. Pregnancy, breast-feeding.
7. Known hypersensitivity to gastrin analogues.
8. Patients with concurrent illnesses that might preclude study completion or interfere with study results.
9. Patients with bladder outflow obstruction or unmanageable urinary incontinence.
10. Clinical diagnosis of disseminated intravascular coagulation.
11. Serum creatinine \>170 μmol/L, GFR \< 40 mL/min
12. Known history of hypersensitivity to gelofusine /gelaspan or any other contraindications to gelofusine/gelaspan infusion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No